556 unknown. 556 Phase 2, 163 Phase 1, 28 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 556 | Unknown 556 |
| Phase 1 | 163 | Unknown 163 |
| Phase 3 | 28 | Unknown 28 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL Polatuzumab vedotin, Rituximab, Orelabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Affiliated Hospital of Nantong University | 30 | 2024-08-01 | 2025-02-04 |
| RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. Thiotepa - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Xianmin Song, MD | 50 | 2024-07-15 | 2024-08-01 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma CMOEP - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 115 | 2024-06-01 | 2024-05-29 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit Ruxolitinib - Hemophagocytic Syndromes | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 42 | 2024-02-01 | 2024-02-06 |
| CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors CD19&CD20 bispecific CAR-T cells - B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-01-14 | 2024-07-16 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Obinutuzumab Combined With Bendamustine - B Cell Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2023-11-30 | 2024-05-16 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma SHR-A1912; R-Chemo - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-11-17 | 2023-12-27 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL ZR2-ICE - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-10-12 | 2024-03-13 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 68 | 2023-10-01 | 2023-10-10 |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Linperlisib in combined with Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 32 | 2023-09-25 | 2023-10-16 |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 20 | 2023-09-10 | 2023-11-01 |
| A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) GFH009 - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Unknown | Genfleet Therapeutics (Shanghai) Inc. | 95 | 2023-09-06 | 2024-12-13 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
Showing 20 of 556. Sign in to see all of them.
Lymphoma (125) · Lymphoma, Large B-Cell, Diffuse (106) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (87) · Lymphoma, Non-Hodgkin (78) · Lymphoma, Follicular (57) · Recurrence (57) · Hodgkin Disease (56) · Lymphoma, B-Cell (50) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Lymphoma, Mantle-Cell (41) · Burkitt Lymphoma (39) · Leukemia (36) · Lymphoma, T-Cell, Peripheral (35) · Lymphoma, B-Cell, Marginal Zone (24) · Leukemia, Myeloid, Acute (23)
Hemic and Lymphatic Diseases (556) · Immune System Diseases (525) · Neoplasms by Histologic Type (525) · Lymphoproliferative Disorders (524) · Immunoproliferative Disorders (522) · Neoplasms (522) · Lymphoma (312) · Lymphoma, Non-Hodgkin (251) · Hematologic Diseases (175) · Leukemia, Lymphoid (139) · Lymphoma, B-Cell (131) · Leukemia (122) · Pathological Conditions, Signs and Symptoms (120) · Pathologic Processes (119)
Cyclophosphamide (80) · Rituximab (76) · Etoposide (43) · Vincristine (39) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (38) · Cytarabine (36) · Doxorubicin (36) · Prednisone (32) · Dexamethasone (27) · Methotrexate (26) · Lenalidomide (25) · fludarabine (24) · Busulfan (18) · Bendamustine Hydrochloride (16) · Gemcitabine (15)
Chinese PLA General Hospital (19) · Ruijin Hospital (15) · Sun Yat-sen University (15) · Fudan University (12) · Peking Union Medical College Hospital (10) · The First Affiliated Hospital of Soochow University (10) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9) · Institute of Hematology & Blood Diseases Hospital, China (9) · Nanfang Hospital, Southern Medical University (7) · Southwest Hospital, China (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Cancer Research UK (6) · Asan Medical Center (5) · Assistance Publique - Hôpitaux de Paris (5) · Chongqing Precision Biotech Co., Ltd (5)
China (258) · United States (65) · South Korea (33) · Italy (29) · Germany (16) · Spain (16) · United Kingdom (15) · France (13) · Israel (13) · Canada (10) · Russia (9) · Denmark (7) · Mexico (6) · Poland (6) · Singapore (5)
Cheng Qian, MD, PhD (5) · Cheng Qian, PhD (5) · Ye Guo, MD (5) · Sanbin Wang, MD (4) · Arnon Nagler, MD (3) · Jun Zhu, MD (3) · Umberto Tirelli, MD (3) · David Cunningham, MD FRCP (2) · David G. Savage, MD (2) · Dehui Zou, Dr. (2) · Eucario Leon Rodriguez, M.D. (2) · Fernando Cabanillas, MD (2) · Graham Collins (2) · Huilai Zhang (2) · Hye Jin Kang, M.D. (2)
PMID 34515338, PMID 40135712, PMID 41671463, PMID 28054442, PMID 31039052, PMID 32632956, PMID 40195173, PMID 10555755, PMID 11123390, PMID 11675328, PMID 12543862, PMID 12712448, PMID 14963856, PMID 15107815, PMID 15201427, PMID 15507947, PMID 15713717, PMID 15725919, PMID 16155013, PMID 16564913, PMID 17134114, PMID 17366834, PMID 17570676, PMID 18213528, PMID 18268188, PMID 18358930, PMID 18824292, PMID 19220526, PMID 19461405, PMID 1950172, PMID 19720922, PMID 20067838, PMID 20371346, PMID 20530974, PMID 20685256, PMID 20686505, PMID 20959411, PMID 21220611, PMID 21374750, PMID 21390126, PMID 21486866, PMID 21502559, PMID 21525172, PMID 21796119, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22080169, PMID 22086414
P30CA060553 (4), 2015 (3), 2017 (3), 2018 (3), 2009 (2), 2004 (1), 2005 (1), 2014 (1), 2016 (1), P30CA015083 (1), P30CA138292 (1), R44CA192576 (1), R44DA049616 (1)